The invention provides anti-IL-13/IL-17 bispecific antibodies, in particular, anti-IL13/IL17 AA, AF and FF antibodies and methods of using the same, including without limitation, methods of using the anti-IL-13/IL-17 bispecific antibodies for treating moderate to severe asthma and/or eosinophilic asthma.